FDA Expands Drug Indication to Delay Type 1 Diabetes Progression in Children as Young as One Year Old

The U.S. Food and Drug Administration has expanded the approved use of teplizumab, marketed as Tzield, to include children as young as one year old for the delay of stage 3 type 1 diabetes in individuals with stage 2 disease.

This update broadens the drug’s indication from the previous threshold of age eight and older, allowing earlier intervention in very young children identified as being at high risk for progressing to insulin-dependent type 1 diabetes.

The expansion follows a priority review by the FDA, during which the agency evaluated data supporting the drug’s use in a younger pediatric population. Teplizumab is an anti-CD3 monoclonal antibody designed to modulate the immune system’s attack on insulin-producing beta cells in the pancreas.

In clinical studies, a single 14-day course of teplizumab has demonstrated a median delay of approximately two years in the onset of stage 3 type 1 diabetes compared to placebo. The drug does not prevent the disease but postpones the need for insulin therapy in those who meet the criteria for stage 2 disease, characterized by the presence of two or more diabetes-related autoantibodies and dysglycemia without overt symptoms.

The FDA’s decision was informed by analyses showing consistent efficacy and safety profiles across age groups, including children under eight years old. Adverse events observed in trials were generally mild to moderate and included cytokine release syndrome, rash, headache, and decreased lymphocyte counts, most of which resolved during or shortly after treatment.

Stage 2 type 1 diabetes represents a critical window for intervention, as individuals in this phase have an approximately 75% risk of developing stage 3 disease within five years. By delaying progression, teplizumab offers a meaningful period without the burden of daily insulin management, blood glucose monitoring, and associated lifestyle disruptions.

Specialists in pediatric endocrinology have noted that earlier access to disease-modifying therapies could improve long-term outcomes by reducing the duration of hyperglycemia exposure during critical developmental years. However, they emphasize that screening for autoantibodies remains limited in routine pediatric care, and broader implementation will depend on increased awareness and access to testing.

Sanofi, the manufacturer of Tzield, stated that the expanded approval reflects ongoing efforts to address the unmet need for therapies that alter the course of type 1 diabetes in its earliest detectable stages. The company continues to monitor long-term outcomes in treated patients through post-marketing studies and registries.

As of this update, Tzield remains the only FDA-approved disease-modifying therapy for delaying symptomatic type 1 diabetes. Its use is restricted to individuals without a diagnosis of stage 3 disease who have confirmed stage 2 status through clinical testing.